Guggenheim analyst Michael Schmidt downgraded Mersana Therapeutics (MRSN) to Neutral from Buy after Day One Biopharmaceuticals (DAWN) agreed to buy the company for $25 per share in cash at closing plus one CVR worth up to an aggregate of $30.25 in cash.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRSN:
- Mersana downgraded to Market Perform from Outperform at LifeSci Capital
- Hold Rating on DAWN’s Acquisition of Mersana Therapeutics: Balancing Opportunities and Risks Amid ACC Focus
- Hold Rating on Mersana Therapeutics Acquisition by Day One Biopharmaceuticals: Strategic Alignment and Risk-Adjusted Valuation
- Mersana Therapeutics downgraded to Market Perform from Outperform at Leerink
- Mersana Therapeutics downgraded to Hold from Buy at Truist